Naked DNA vaccines represent an attractive approach for generating antigen-specific immunity because of their stability and simplicity of delivery. There are particular concerns with DNA vaccines however, such as potential integration into the host genome, cell transformation, and limited potency. The usage of DNA-based alphaviral RNA replicons (suicidal DNA vectors) may alleviate the concerns of integration or transformation since suicidal DNA vectors eventually cause lysis of transfected cells. To improve further the potency of suicidal DNA vaccines, we evaluated the effect of linking Mycobacterium tuberculosis heat shock protein 70 (Hsp70) to human papillomavirus type 16 (HPV-16) E7 as a model antigen on antigen-specific immunity generated by a
Introduction
Nucleic acid vaccines have recently emerged as a promising approach for vaccine development (for review, see Refs 1 and 2). The use of naked DNA for vaccination has the advantages of purity, simplicity of preparation, and stability. In addition, DNA-based vaccines can be prepared inexpensively and rapidly in large-scale. Furthermore, multiple DNA vaccines can be administered simultaneously. However, naked DNA vaccines raise certain concerns such as potential integration into the host genome and cell transformation. Another concern about DNA vaccines is their potency since they do not have the intrinsic ability to amplify in vivo as viral vaccines do.
More recently, RNA replicon vaccines have emerged as an important strategy to alleviate the concerns for potential chromosomal integration and cell transformation generated by the use of conventional DNA vaccines. 3 These vaccines are self-replicating and self-limiting and may be administered as either RNA or DNA, which is then transcribed into RNA replicons in transfected cells or in vivo. DNA-based self-replicating RNA DNA-based Semliki Forest virus (SFV) RNA vector, pSCA1. Our results indicated that this suicidal DNA vaccine containing E7/Hsp70 fusion genes generated significantly higher E7-specific T cell-mediated immune responses than vaccines containing the wild-type E7 gene in vaccinated mice. More importantly, this fusion converted a less effective vaccine into one with significant potency against established E7-expressing metastatic tumors. The antitumor effect was predominantly CD8-dependent. These results indicate that linkage of Hsp70 to the antigen may greatly enhance the potency of suicidal DNA vaccines. Gene Therapy (2001) 8, 376-383.
replicons, also known as 'suicidal DNA', eventually cause lysis of transfected cells. 4, 5 We developed our vaccine using the Semliki Forest virus suicidal DNA vector, pSCA1. 6 These vectors do not raise the concern associated with naked DNA vaccines of integration into the host genome. This feature is particularly important for vaccine development targeting potentially oncogenic proteins, such as the HPV E7 protein. 7 Because suicidal DNA vectors eventually lead to apoptosis of transfected cells, the expression of inserted genes in these vectors is transient and the potency of suicidal DNA vaccines may be compromised. Therefore, it is important to consider strategies to enhance the potency of suicidal DNA vaccines.
Recently, we demonstrated that linkage of Mycobacterium tuberculosis heat shock protein 70 (Hsp70) to the HPV-16 E7 antigen enhanced the potency of a conventional naked DNA vaccine. 8 In the past few years, studies have demonstrated that immunization with HSP complexes isolated from tumors or virus-infected cells are able to induce potent antitumor 9 or antiviral immunity.
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Immunogenic Hsp70-peptide complexes can also be reconstituted in vitro by mixing the peptides with HSPs.
11
Hsp70-based protein vaccines can also be administered by fusing antigens to HSPs. 12 These investigations have made HSPs more attractive for use in immunotherapy. However, the Hsp70 vaccines that have been tested thus far are in the form of protein-based vaccines or conventional DNA-based vaccines. To date, HSPs have not been applied in the form of suicidal DNA vaccines.
In our current study, we investigated whether linkage of full-length Hsp70 to E7 can enhance the potency of suicidal DNA vaccines. We showed that the suicidal DNA vaccine, pSCA1-E7/Hsp70, significantly increased expansion and activation of E7-specific CD8 + T cells compared with pSCA1-E7. This enhanced CD8 response resulted in potent antitumor immunity against an E7-expressing tumor cell line.
Results
Construction and characterization of the pSCA1-E7/Hsp70 suicidal DNA vaccine The generation of plasmid DNA constructs and subsequent preparation of DNA-based self-replicating pSCA1 vaccines was performed as described in Materials and methods. The pSCA1 vector contains the HCMV IE promoter and a replicon from the Semliki Forest virus. 6 A schematic diagram depicting DNA-based self-replicating pSCA1-E7, pSCA1-Hsp70, and pSCA1-E7/Hsp70 constructs is shown in Figure 1 . Since the level of E7 protein expression may be relevant to the vaccine effect, we have performed an ELISA using BHK21 cells transfected with various DNA-based self-replicating E7-containing pSCA1 DNA constructs. Similar amounts of E7 protein were expressed by each of these constructs (data not shown).
Vaccination with the pSCA1-E7/Hsp70 suicidal DNA vaccine enhances E7-specific CD8 + T cell-mediated immune responses CD8 + T lymphocytes are one of the most crucial effectors for inducing antitumor immunity. To determine the quantity of E7-specific CD8 + T cell precursors generated by the DNA-based self-replicating pSCA1-E7/Hsp70 vaccine, intracellular cytokine staining was performed on splenocytes extracted from mice vaccinated with various suicidal DNA vaccines intradermally via gene gun. As shown in Figure 2a , vaccination of mice with pSCA1-E7/Hsp70 suicidal DNA vaccine generated the highest number of E7-specific IFN-␥ + CD8 + T cell precursors (40/3 × 10 5 splenocytes) compared with vaccination with pSCA1-E7 DNA (9/3 × 10 5 splenocytes) (P Ͻ 0.01). pSCA1-E7/Hsp70 DNA immunization led to a nearly four-fold increase in the number of E7-specific CD8 + T cell precursors. The mean number of IFN-␥-producing E7-specific CD8 + T cells was determined in the presence (solid columns) and absence (open columns) of E7 pep- tide (aa 49-57, RAHYNIVTF) and shown in Figure 2b . These results indicated that linkage of Hsp70 to E7 significantly enhanced E7-specific CD8 + T cell precursors in mice vaccinated with suicidal DNA vaccines.
Vaccination with pSCA1-E7/Hsp70 suicidal DNA vaccine does not generate significant E7-specific CD4 + T cellmediated immune responses To examine whether various pSCA1 suicidal DNA vaccines generated E7-specific CD4
+ T precursor cells and relevant cytokine profiles, we performed double staining for CD4 surface marker and intracellular IFN-␥ or IL-4 on splenocytes obtained from immunized mice, followed by flow cytometry analysis. The percentage of IFN-␥-secreting CD4
+ T cells was analyzed using flow cytometry. As shown in Figures 3a and b , there was no significant difference in the number of E7-specific IFN-␥-secreting or IL-4-secreting CD4
+ cells observed using flow cytometry staining among the various vaccination groups. These results indicated that linkage of Hsp70 to 
E7 did not enhance E7-specific CD4
+ T cell precursors in mice vaccinated with suicidal DNA vaccines.
Vaccination with pSCA1-E7/Hsp70 suicidal DNA vaccine does not enhance the generation of E7-specific antibodies The quantity of anti-HPV 16 E7 antibodies in the sera of the vaccinated mice was determined using a direct ELISA 2 weeks after vaccination at various dilutions (1:100, 1:500, 1:1000). The pSCA1-E7/Hsp70 vaccine did not generate higher titers of E7-specific antibodies in the sera of vaccinated mice compared with those generated by the pSCA1-E7 vaccine (Figure 4 ).
Vaccination with pSCA1-E7/Hsp70 suicidal DNA vaccine enhances protection of mice against the growth of TC-1 tumors To determine whether vaccination with the DNA-based self-replicating pSCA1-E7/Hsp70 vaccine protects mice against E7-expressing tumors, in vivo tumor protection experiments were performed using an E7-expressing tumor cell line, TC-1, in C57BL/6 mice. As shown in Figure 5 , 80% of those receiving DNA-based self-replicating pSCA1-E7/Hsp70 DNA vaccination remained tumor-free 70 days after TC-1 challenge. In contrast, all of the mice receiving pSCA1 without wild-type pSCA1-E7, or pSCA1-Hsp70, as well as all of the naive mice developed tumors within 2 weeks. Therefore, DNAbased self-replicating pSCA1-E7/Hsp70 vaccine significantly enhanced the antitumor immunity against the growth of E7-expressing tumors. 
CD8
+ T cells are essential for the antitumor effect generated by pSCA1-E7/Hsp70 suicidal DNA vaccine To determine the subset of lymphocytes that are important for the rejection of E7-positive tumor cells, we performed in vivo antibody depletion experiments. As shown in Figure 7 , all naive mice and all of the mice depleted of CD8 + T cells grew tumors within 10 days after tumor challenge. In contrast, 80% of the nondepleted mice remained tumor free 40 days after tumor challenge. Forty percent of CD4 and NK1.1-depleted mice grew tumors 2 weeks after tumor injections. These results suggest that CD8 + T cells are essential for E7-specific antitumor immunity generated by the pSCA1-E7/Hsp70 suicidal DNA vaccine. CD4 and NK1.1 cells may also contribute to the antitumor effect generated by the pSCA1-E7/Hsp70 sucidal DNA vaccine, although their degree of contribution is considerably less than that of CD8 + T cells.
Discussion
In this study, we demonstrated that linkage of Hsp70 to E7 can significantly enhance the potency of HPV-16 E7-expressing DNA-based self-replicating RNA replicon vaccines. Suicidal DNA vaccines incorporating Hsp70 fused to HPV-16 E7 generated significant E7-specific
Gene Therapy CD8 + T cell-mediated immune responses. Furthermore, the chimeric pSCA1-E7/Hsp70 suicidal DNA vaccine was capable of preventing lethal pulmonary metastatic E7-expressing tumors.
Enhancement of CD8 + T cell activity is important for generating potent antitumor responses (for review, see . The pSCA1-E7/Hsp70 suicidal DNA vaccine augmented E7-specific CD8 + T cell activity, resulting in significant tumor protection and treatment against E7-expressing TC-1 tumor cells. Furthermore, depletion of CD8 + CTL led to loss of the antitumor effect. Activated CTL can function directly as effector cells, providing antitumor immunity through the lysis of tumor cells or through the release of cytokines capable of interfering with the propagation of tumors. Therefore, the enhancement of antitumor CD8 + T cell activity is critical to the potent effect generated by the pSCA1-E7/Hsp70 vaccine.
One of the potential mechanisms for the enhancement of E7-specific CD8 + T cell responses in vivo is the direct MHC class I presentation of E7 to CD8 + T cells by antigen presenting cells (APCs) expressing E7/HSP70, a process known as 'direct priming'. However, since the suicidal DNA vaccine eventually results in the apoptosis of transfected cells, it is unlikely that the transfected APCs can present antigen through direct priming pathway in an efficient manner.
The enhanced E7-specific CD8 + T cell responses by pSCA1-E7/Hsp70 in vaccinated mice is likely generated through a so-called 'cross-priming' effect, 16 whereby cells expressing E7/HSP70 antigen release exogenous protein to be taken up and processed by other antigen-presenting cells (APCs) via the MHC class I-restricted pathway. Cross-priming is a likely mechanism for the enhancement of CD8 + T cell activity since suicidal DNA eventually causes lysis of transfected cells, 17 which probably release antigen to other APCs. Previous studies have reported that Hsp70 can be linked to malaria peptide (NANP)40, 18 HIV-1 p24, 12 ovalbumin, 19 or influenza nucleoprotein 20 and be administered as exogenous protein to enhance MHC class I presentation of linked antigens. Hsp70 fusion proteins are probably taken up by professional APCs, which have been shown to play an important role in presenting exogenous Hsp70-associated antigens through the MHC class I pathway. 21, 22 It has been suggested that Hsp70 complexes can enter into professional APCs via receptor-mediated endocytosis. 23 More recently, Cho et al 24 reported that mycobacterial heat shock protein fused to antigen could stimulate dendritic cells in vitro and in vivo to up-regulate the level of MHC class I and II and costimulatory molecules. The lytic nature of the pSCA1 vector and the potential enhancement of MHC-I processing and maturation of dendritic cells induced by Hsp70 linked to antigen may therefore contribute to augmentation of CD8 + T cell activity generated by the pSCA1-E7/Hsp70 vaccine via a cross-priming pathway.
One issue concerning the safety of E7/Hsp70 suicidal DNA vaccine is the induction of apoptosis by suicidal DNA. This observation raises the concern for potential tissue damage after administration of suicidal DNA vaccines. Nevertheless, we performed pathological examination of the vital organs in the pSCA1-E7/Hsp70-vaccinated mice and did not observe any significant pathological changes (data not shown). Another issue concerns potential risks associated with the presence of HPV-16 E7 protein in host cells. E7 is a viral oncoprotein that disrupts cell cycle regulation by binding to tumor suppressor pRB protein in nuclei. 25 Thus, the presence of E7 in host cells may lead to accumulation of genetic aberrations and eventual malignant transformation in the host cells. The usage of the suicidal DNA vector may ease the concern for oncogenicity of E7 protein since the cells transfected with the vector will eventually undergo apoptotic changes. In addition, the oncogenicity of E7 can be further eliminated by introducing mutations into E7 DNA so that the resulting E7 protein cannot bind with pRB 26 but still maintains most of its antigenicity. In summary, our results reveal that fusion of a gene encoding Mycobacterium tuberculosis Hsp70 to HPV-16 E7 gene in a suicidal DNA vaccine can generate significant E7-specific CD8 + T cell-mediated immune responses and antitumor effects against HPV-16 E7-expressing murine tumors. Since a majority of cervical cancers express HPV E7, our vaccine can potentially be used for the control of HPV-associated tumors. Furthermore, the strategy of fusing HSP70 to an antigen gene may be applied to other infectious diseases and cancer systems. Because DNAbased RNA replicon vaccines are stable and easy to prepare in mass quantities, such vaccines are particularly desirable in developing countries which have a high prevalence of HPV-associated cervical malignancy and lack the facilities to store biological agents.
Materials and methods
Plasmid DNA constructs and preparation pSCA1 vector 6 was a generous gift from Dr Rod Bremner at the University of Toronto. This pSCA1 vector contains human cytomegalovirus immediate-early gene (HCMV IE) promoter upstream of the Semliki Forest virus replicon. The subgenomic promoter is located after the Semliki Forest virus replicon, upstream of a multiple cloning site for the insert of genes of interest. For the generation of pSCA1-E7, E7 was cut from pcDNA3-E7 8 by BamHI/PmeI and cloned into BamHI/SmaI sites of pSCA1. To construct pSCA1-Hsp70, Hsp70 was cut from pcDNA3-Hsp70 8 by BamHI/PmeI and cloned into BamHI/SmaI sites of pSCA1. For the generation of pSCA1-E7/Hsp70, E7/Hsp70 DNA was cut from pcDNA3-E7/Hsp70 8 by BamHI/PmeI and cloned into BamHI/SmaI sites of pSCA1. The accuracy of these constructs was confirmed by DNA sequencing. Plasmid DNA vectors encoding pSCA1-E7, pSCA1-Hsp70, pSCA1-E7/Hsp70 or pSCA1 with no insert were transfected into subcloning efficient DH5 cells (Life Technologies, Rockville, MD, USA). The DNA was then ampli- fied and purified as described previously. 8 The integrity of plasmid DNA and the absence of Escherichia coli DNA or RNA were checked in each preparation using 1% agarose gel electrophoresis. DNA concentration was determined by the optical density measured at 260 nm. The presence of inserted E7 fragment was confirmed by restriction enzyme digestion and gel electrophoresis.
Cell lines
The production and maintenance of TC-1 cells has been described previously. 27 In brief, HPV-16 E6, E7 and ras oncogene were used to transform primary C57BL/6 mouse lung epithelial cells. The cells were grown in RPMI 1640, supplemented with 10% (v/v) fetal bovine serum, antibiotics, l-glutamine, sodium pyruvate, nonessential amino acids at 37°C with 5% CO 2 . On the day of tumor challenge, TC-1 cells were harvested by trypsinization, washed twice with 1× Hank's buffered salt solution (HBSS) and finally resuspended in 1× HBSS to the designated concentration for injection.
Mice Six-to 8-week-old female C57BL/6 mice from the National Cancer Institute (Frederick, MD, USA) were purchased and kept in the oncology animal facility of the Johns Hopkins Hospital (Baltimore, MD, USA). All animal procedures were performed according to approved protocols and in accordance with recommendations for the proper use and care of laboratory animals.
Gene Therapy DNA vaccination Gene gun particle-mediated DNA vaccination was performed using a helium-driven gene gun (Bio-rad, Hercules, CA, USA) according to the protocol provided by the manufacturer. Briefly, DNA-coated gold particles were prepared by combining 25 mg of 1.6 m gold microcarriers (Bio-rad) and 100 l of 0.05 m spermidine (Sigma, St Louis, MO, USA). Plasmid DNA (50 g) and 1.0 m CaCl 2 (100 l) were added sequentially to the microcarriers while mixing by vortex. This mixture was allowed to precipitate at room temperature for 10 min. The microcarrier/DNA suspension was then centrifuged (10 000 r.p.m. for 5 s) and washed three times in fresh absolute ethanol before resuspension in 3 ml of polyvinylpyrrolidone (0.1 mg/ml) (Bio-rad) in absolute ethanol. The solution was then loaded into tubing and allowed to settle for 4 min. The ethanol was gently removed and the microcarrier/DNA suspension was evenly attached to the inside surface of the tubing by rotating the tube. The tube was then dried using 0.4 liters per minute of flowing nitrogen gas. The dried tubing coated with microcarrier/DNA was then cut to 0.5-inch cartridges and stored in a capped dry bottle at 4°C. As a result, each cartridge contained 1 g of plasmid DNA and 0.5 mg of gold. The DNA-coated gold particles (1 g DNA per bullet) were delivered to the shaved abdominal region of the mice using a helium-driven gene gun (Biorad) with a discharge pressure of 400 p.s.i.
Intracytoplasmic cytokine staining and flow cytometry analysis Splenocytes from naive or vaccinated groups of mice were incubated with either the E7 peptide (aa 49-57, RAHYNIVTF) containing MHC class I epitope 28 or the E7 peptide (aa 30-67) containing MHC class II epitope. 29 The E7 peptide was added at a concentration of 2 g/ml for 20 h. To detect E7-specific CD8 + T cell precursors and E7-specific CD4 + T helper cell responses, CD8 + CTL epitope aa 49-57 and CD4 + T helper epitope aa 30-67 were used, respectively. Golgistop (Pharmigen, San Diego, CA, USA) was added 6 h before harvesting the cells from the culture. Cells were then washed once in FACScan buffer and stained with phycoerythrin (PE)-conjugated monoclonal rat anti-mouse CD8 or CD4 antibody (PharMingen, San Diego, CA, USA). Cells were subjected to intracellular cytokine staining using the Cytofix/Cytoperm kit according to the manufacturer's instructions (PharMingen). FITC-conjugated anti-IFN-␥ or anti-IL-4 antibodies and the immunoglobulin isotype control antibody (rat IgG1) were all purchased from PharMingen. Analysis was done on a Becton Dickinson FACScan with CELLQuest software (Becton Dickson Immunocytometry System, Mountain View, CA, USA).
ELISA for serum E7 antibody
The anti-HPV 16 E7 antibodies in the sera were determined by a direct ELISA as previously described. 30 A 96-microwell plate was coated with 100 l 1 g/ml bacteriaderived HPV-16 E7 proteins and incubated at 4°C overnight. The wells were then washed and blocked with PBS containing 20% fetal bovine serum. Sera were prepared from the mice on day 14 after immunization, serially diluted in PBS, added to the ELISA wells, and incubated at 37°C for 2 h. After washing with PBS containing 0.05% Tween-20, the plate was incubated with 1/2000 dilution of a peroxidase-conjugated rabbit anti-mouse IgG antibody (Zymed, San Francisco, CA, USA) at room temperature for 1 h. The plate was washed six times, developed with TMB (Pierce, Rockford, IL, USA), and stopped with 1 m H 2 SO 4 . The ELISA plate was read with a standard ELISA reader at 450 nm.
In vivo tumor protection experiments
For the tumor protection experiment, mice (five per group) were vaccinated via gene gun with 2 g of pSCA1-E7, pSCA1-Hsp70, pSCA1-E7/Hsp70 DNA, or pSCA1 without insert. One week later, the mice were boosted with the same regimen as the first vaccination. One week after the last vaccination, mice were subcutaneously challenged with 1 × 10 4 cells per mouse TC-1 tumor cells in the right leg and then monitored twice a week.
In vivo tumor treatment experiments
The tumor cells and DNA vaccines were prepared as described earlier. Mice (5 per group) were intravenously challenged with 1 × l0 4 cells per mouse TC-1 tumor cells via tail vein on day 0. Three days after challenge with TC-1 tumor cells, mice were given 2 g of pSCA1-E7, pSCA1-Hsp70, pSCA1-E7/Hsp70 DNA, or pSCA1 without insert via gene gun. One week later, these mice were boosted with the same regimen as the first vaccination. The mice were killed on day 21. The number of tumor nodules on the surface of the lung of each mouse was evaluated and counted by experimenters blinded to sample identity.
In vivo antibody depletion experiments
In vivo antibody depletions have been described previously. 27 Briefly, mice (5 per group) were vaccinated with 2 g DNA via gene gun, boosted 1 week later, and challenged with 5 × 10 4 cells per mouse TC-1 tumor cells. Depletions were started 1 week before tumor challenge. MAb GK1.5 31 was used for CD4 depletion, MAb 2.43 32 was used for CD8 depletion, and MAb PK136 33 was used for NK1.1 depletion. Flow cytometry analysis revealed that Ͼ95% of the appropriate lymphocyte subsets were depleted with normal levels of other subsets. Depletion was terminated on day 40 after tumor challenge.
